Figure 6 | Scientific Reports

Figure 6

From: Pharmacoproteomic analysis reveals that metapristone (RU486 metabolite) intervenes E-cadherin and vimentin to realize cancer metastasis chemoprevention

Figure 6

The schematic representation represents the MET potential of metapristone in MDA-MB-231 cells.

Metapristone inhibits EMT by regulating TGF-β or Wnt signaling pathways. Metapristone inhibits EMT through Smad or non-Smad pathways involved in TGF-β signaling pathway, which results in suppression of mesenchymal and up-regulation of epithelial marker expression. Metapristone depressed EMT through regulating Wnt signaling pathway mediated by β-catenin and caveolin.

Back to article page